28 augustus 2021: Bron: 2021; 11: 686950. Published online 2021 Jun 10

Groene thee - epigallocatechin-3-gallate (EGCG) extract vergroot respons van bestraling, vermindert bijwerkingen en geeft langere progressievrije ziekte en betere overall overleving bij longkankerpatiënten die bestraald waren.

Uit een gerandomiseerde fase II studie bij longkankerpatiënten die bestraald waren blijkt dat wanneer groene thee - epigallocatechin-3-gallate (EGCG) werd gebruikt naast de radiotherapie dat het verschil in ziekte progressieve overleving (PFS) veel beter was in vergelijking met alleen bestraling (33 vs 9.3 procent).

Ook de bijwerkingen, met name beschadiging van de slokdarm (was in de groep patiënten die het groene thee extract hadden gekregen veel minder. De overall overleving was ook wel beter maar door het kleine aantal patienten (totaal 86 longkankerpatiënten deden mee aan de studie) was dit niet statistisch significant (33 vs 30 procent op 5-jaar. Het objectieve responspercentage (ORR) was hoger voor de groene thee groep (EGCG) in vergelijking met de andere groep die alleen was bestraald en geen groene thee extract (ECGC) had gekregen. (84,6 versus 50%, P = 0,045).

Het studiderapport is gratis in te zien. Klik op de titel van het abstract voor het volledige studierapport:

. 2021 Jun 10;11:686950.

doi: 10.3389/fonc.2021.686950. eCollection 2021.

Evaluation of Epigallocatechin-3-Gallate as a Radioprotective Agent During Radiotherapy of Lung Cancer Patients: A 5-Year Survival Analysis of a Phase 2 Study

Wanqi Zhu 1 2 3, Yalan Zhao 4, Shuyu Zhang 5, Xiaolin Li 3, Ligang Xing 4, Hanxi Zhao 3, Jinming Yu 1 2 3

Affiliations

PMID: 34178681
PMCID: PMC8223749
DOI: 10.3389/fonc.2021.686950

Free PMC article

Abstract

Background: Previous analysis of the study (NCT02577393) had demonstrated the application of epigallocatechin-3-gallate (EGCG) could be safe and effective in the prevention and treatment of acute radiation esophagitis in patients with advanced lung cancer. EGCG seemed to improve the response rate of small cell lung cancer (SCLC) to radiotherapy in a subgroup analysis. This research continued to analyze the impact of EGCG application on cancer-radiation efficacy and patient survival.

Methods: All patients with SCLC in the NCT02577393 study were included. Patients were randomized into EGCG group or conventional therapy group as protocol. The primary endpoints of the study were radiation response rate and progression-free survival (PFS). Overall survival (OS) and the efficacy of EGCG in the treatment of esophagitis were assessed as secondary endpoints.

Results: A total of 83 patients with lung cancer in the NCT02577393 study were screened, and all 38 patients with SCLC were eligible for analysis. No significant differences with regard to baseline demographic and clinical characteristics were observed between the two groups. The objective response rate (ORR) was higher than that of conventionally treated patients (84.6 vs 50%, P = 0.045), while the median PFS and OS were not significantly prolonged. At data cut-off (1 January 2021), 5-year PFS was 33% with EGCG versus 9.3% with conventional treatment, and 5-year OS was 30.3% versus 33.3%, respectively. The mean adjusted esophagitis index and pain index of patients with EGCG application were lower than conventional treatment (5.15 ± 2.75 vs 7.17 ± 1.99, P = 0.030; 8.62 ± 5.04 vs 15.42 ± 5.04, P < 0.001).

Conclusion: The study indicates EGCG may alleviate some esophagitis-related indexes in SCLC patients exposed to ionizing radiation without reducing survival. However, this conclusion should be confirmed by further studies with large sample size.

Keywords: Epigallocatechin-3-gallate; long-term follow-up; lung cancer; radiation-induced esophagitis; radioprotective agent.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.